Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EOM613
- Development stage
- Phase 2
- Lead developer
- EOM Pharmaceutical
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
**EOM613** is an investigational peptide-nucleic acid immunomodulator developed by EOM Pharmaceuticals. The agent is described as a dynamically dual-acting, broad-spectrum immune regulator that can suppress or stimulate monocytes and macrophages according to their activation state and local immune environment. It is intended to rebalance dysregulated cytokine responses rather than selectively inhibit a single cytokine pathway. EOM613 has been evaluated in severe hospitalized COVID-19, HIV/AIDS-associated cachexia, cancer cachexia, and rheumatoid arthritis, with further development planned for Crohn's disease.
- Brand names
- Reticulose
- Other names
- Product ROHR/AVR118
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on EOM613.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EOM613.